Evaxion names Helen Tayton-Martin as new CEO
Source: SeekingAlpha
2025-10-27 08:13:57 ET
More on Evaxion Biotech ADS
- Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript
- Evaxion A/S (EVAX) Presents at BioTechX Europe 2025 - Slideshow
- Evaxion A/S (EVAX) Out-Licenses Vaccine Candidate EVX-B3 To MSD Presentation - Slideshow
- Merck in-licenses Evaxion vaccine candidate in a deal worth up to $600M
- Seeking Alpha’s Quant Rating on Evaxion Biotech ADS
Read the full article on Seeking Alpha
For further details see:
Evaxion names Helen Tayton-Martin as new CEO
Evaxion Biotech A/S
NASDAQ: EVAX
EVAX Trading
-2.2% G/L:
$4.225 Last:
60,264 Volume:
$4.25 Open:
EVAX Latest News
March 02, 2026 08:00:00 am
Evaxion to announce business update and full year 2025 financial results on March 5, 2026
EVAX Stock Data
$28,519,826
7,782,965
N/A
6
N/A
Biotechnology & Life Sciences
Healthcare
DK
Hoersholm
